Irene Lau

Irene Lau has a diverse range of work experience in the field of business development and finance. Irene is currently working at Intellia Therapeutics, Inc. as the Vice President of Business Development, a position they have held since January 2023. Prior to this, they served as the Senior Director of Business Development from April 2021 to January 2023, and as the Director of Business Development from December 2019 to April 2021.

Before joining Intellia Therapeutics, Inc., Irene worked at Alnylam Pharmaceuticals where they held various roles related to business development and strategy. Irene was an Associate Director of Business Development from August 2018 to November 2019, an Associate Director of Strategy from August 2017 to July 2018, and held positions in strategy and business analysis from July 2016 to July 2017 and from May 2015 to July 2016.

Prior to their time at Alnylam Pharmaceuticals, Irene worked in the finance industry. Irene was a Biotech Equity Research Associate at Goldman Sachs from May 2014 to May 2015, a Biotech Equity Research Associate at Leerink Swann from June 2012 to 2014, and a Biotech Research Associate at ThinkEquity LLC from July 2011 to October 2012. Irene also worked as a Healthcare Investment Banking Analyst at Oppenheimer & Co. from July 2008 to September 2010, and interned at Merrill Lynch in June 2007.

Overall, Irene Lau has a strong background in business development, strategy, and finance, with significant experience in the biotech industry.

Irene Lau obtained a Bachelor of Science degree in Microbiology from the University of California, Berkeley in 2008.